MA41997A - Combinaisons de cannabinoïdes et de n-acyléthanolamines - Google Patents

Combinaisons de cannabinoïdes et de n-acyléthanolamines

Info

Publication number
MA41997A
MA41997A MA041997A MA41997A MA41997A MA 41997 A MA41997 A MA 41997A MA 041997 A MA041997 A MA 041997A MA 41997 A MA41997 A MA 41997A MA 41997 A MA41997 A MA 41997A
Authority
MA
Morocco
Prior art keywords
acylethanolamines
cannabinoids
combinations
Prior art date
Application number
MA041997A
Other languages
English (en)
French (fr)
Inventor
Ephraim Brener
Elran Haber
Ascher Shmulewitz
Original Assignee
Therapix Biosciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Therapix Biosciences Ltd filed Critical Therapix Biosciences Ltd
Publication of MA41997A publication Critical patent/MA41997A/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/658Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/164Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/348Cannabaceae
    • A61K36/3482Cannabis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
MA041997A 2015-04-29 2016-04-19 Combinaisons de cannabinoïdes et de n-acyléthanolamines MA41997A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562154144P 2015-04-29 2015-04-29

Publications (1)

Publication Number Publication Date
MA41997A true MA41997A (fr) 2021-03-31

Family

ID=57199061

Family Applications (1)

Application Number Title Priority Date Filing Date
MA041997A MA41997A (fr) 2015-04-29 2016-04-19 Combinaisons de cannabinoïdes et de n-acyléthanolamines

Country Status (12)

Country Link
US (7) US11234956B2 (enExample)
EP (2) EP4193993A3 (enExample)
JP (2) JP6938465B2 (enExample)
CN (2) CN107530317A (enExample)
AU (3) AU2016254685B2 (enExample)
CA (1) CA2984088C (enExample)
DK (1) DK3288553T3 (enExample)
ES (1) ES2935605T3 (enExample)
IL (2) IL291864A (enExample)
MA (1) MA41997A (enExample)
PL (1) PL3288553T3 (enExample)
WO (1) WO2016174661A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107530317A (zh) * 2015-04-29 2018-01-02 希拉匹克斯生物科学有限公司 大麻素类和n‑酰基乙醇胺的组合
US20210052478A1 (en) * 2018-01-05 2021-02-25 Altus Labs, Llc Personal care compositions
WO2019145783A1 (en) * 2018-01-29 2019-08-01 Therapix Biosciences Ltd. Compositions and methods for treating obstructive sleep apnea
EP3773512A4 (en) * 2018-04-03 2021-12-29 Pure Green, LLC Tablet or composition having n-acyl ethanolamine and cannabinoid
WO2020160452A1 (en) * 2019-02-01 2020-08-06 Tess Ventures, Inc. Combining serms, sarms, and cannabinoids for improving safety and efficacy of endocrine therapies
AU2020260090C9 (en) * 2019-04-15 2023-08-31 Metagenics LLC Novel hemp and PEA formulation and its use
CA3134885A1 (en) * 2019-04-23 2020-10-29 SciSparc Ltd. Compositions and methods for potentiating derivatives of 4-aminophenols
WO2020227440A1 (en) * 2019-05-07 2020-11-12 Ojai Energetics Pbc Methods for optimized cannabinoid dosage determination
US12491200B2 (en) 2019-05-23 2025-12-09 Igc Pharma Ip, Llc Compositions and methods using cannabinoids for treating stammering/stuttering and symptoms of Tourette syndrome
EP4017486A4 (en) * 2019-08-19 2023-09-20 Buzzelet Development And Technologies Ltd COMPOSITIONS FOR THE TREATMENT OF A CONDITION CHARACTERIZED BY ANANDAMIDE DEFICIENCY AND THEIR USES
EP3838346A1 (en) * 2019-12-20 2021-06-23 Chemo Research SL Soft gelatin capsules comprising palmitoylethanolamide and alpha-lipoic acid
WO2021141959A1 (en) 2020-01-10 2021-07-15 Pacira Pharmaceuticals, Inc. Treatment of pain by administration of sustained-release liposomal anesthetic compositions
US20230080593A1 (en) 2020-01-10 2023-03-16 Pacira Pharmaceuticals, Inc. Treatment of pain by subarachnoid administration of sustained-release liposomal anesthetic compositions
US11273122B2 (en) 2020-02-11 2022-03-15 Therese Mainella Combination of cannabis, derivatives thereof and additives in oral care compositions
US11918688B2 (en) 2021-01-11 2024-03-05 Pacira Pharmaceuticals, Inc. Treatment of hip pain with sustained-release liposomal anesthetic compositions
US20230000936A1 (en) * 2021-06-30 2023-01-05 Demetrix, Inc. Alleviation of itching sensations using cannabinoid compounds
WO2023039419A2 (en) 2021-09-08 2023-03-16 Plantible Foods Inc. Systems and methods for measuring mat density of aquatic biomass
JP2025512495A (ja) 2022-04-12 2025-04-17 シャッケルフォード・ファーマ・インコーポレーテッド 発作性障害の治療
US11918565B1 (en) 2022-11-03 2024-03-05 Pacira Pharmaceuticals, Inc. Treatment of post-operative pain via sciatic nerve block with sustained-release liposomal anesthetic compositions
US12226610B2 (en) 2022-11-03 2025-02-18 Pacira Pharmaceuticals, Inc. Treatment of pain associated with total knee arthroplasty with sustained-release liposomal anesthetic compositions
WO2024124354A1 (en) * 2022-12-16 2024-06-20 Aima Inc. Compositions and methods for treating or preventing pain or other disorders

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2330681C (en) * 1998-05-29 2008-08-26 Andrea Giuffrida Control of pain with endogenous cannabinoids
US6949582B1 (en) * 1999-05-27 2005-09-27 Wallace Walter H Method of relieving analgesia and reducing inflamation using a cannabinoid delivery topical liniment
GB2394894B (en) * 2002-11-04 2005-08-31 G W Pharma Ltd New use for pharmaceutical composition
WO2007006319A2 (en) 2005-07-14 2007-01-18 Rheoscience A/S Inhibitors of anorexic lipid hydrolysis for the treatment of eating disorders
GB2432312A (en) * 2005-11-01 2007-05-23 Gw Pharma Ltd Pharmaceutical compositions for the treatment of pain
PL2796129T3 (pl) * 2009-09-07 2015-11-30 Epitech Group S P A Kompozycja zawierająca palmitoiloetanoloamid poddany ultramikronizacji
AT509000B1 (de) * 2009-10-23 2012-12-15 Rausch Peter Wasserlösliche zubereitungen von cannabinoiden und cannabispräparaten und deren anwendungen
GB2495118B (en) * 2011-09-29 2016-05-18 Otsuka Pharma Co Ltd A pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD)
EP2719375A1 (en) * 2012-10-10 2014-04-16 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Cannabinoids for the treatment of cancers dependent on hedgehog mechanisms
CN107530317A (zh) * 2015-04-29 2018-01-02 希拉匹克斯生物科学有限公司 大麻素类和n‑酰基乙醇胺的组合

Also Published As

Publication number Publication date
US20180078523A1 (en) 2018-03-22
US11207290B2 (en) 2021-12-28
DK3288553T3 (da) 2023-01-23
US20200038367A1 (en) 2020-02-06
AU2023251426A1 (en) 2023-11-09
IL291864A (en) 2022-06-01
JP6938465B2 (ja) 2021-09-22
US20200022946A1 (en) 2020-01-23
PL3288553T3 (pl) 2023-03-20
AU2016254685A1 (en) 2017-11-09
CA2984088A1 (en) 2016-11-03
AU2023251426B2 (en) 2025-11-27
AU2021206784B2 (en) 2023-07-20
US20210393577A1 (en) 2021-12-23
EP4193993A2 (en) 2023-06-14
US20200030281A1 (en) 2020-01-30
EP4193993A3 (en) 2023-07-19
US20220071949A1 (en) 2022-03-10
EP3288553A1 (en) 2018-03-07
WO2016174661A1 (en) 2016-11-03
EP3288553A4 (en) 2018-12-26
IL255238B (en) 2022-05-01
IL255238A0 (en) 2017-12-31
EP3288553B1 (en) 2022-12-28
CN107530317A (zh) 2018-01-02
US20220071948A1 (en) 2022-03-10
US11234956B2 (en) 2022-02-01
US11197845B2 (en) 2021-12-14
CN116549437A (zh) 2023-08-08
JP2021107401A (ja) 2021-07-29
JP2018514589A (ja) 2018-06-07
AU2021206784A1 (en) 2021-08-12
CA2984088C (en) 2024-04-09
AU2016254685B2 (en) 2021-04-22
ES2935605T3 (es) 2023-03-08

Similar Documents

Publication Publication Date Title
MA41997A (fr) Combinaisons de cannabinoïdes et de n-acyléthanolamines
IL282048A (en) Oxysterols and methods of use thereof
HUE052373T2 (hu) Szubsztituált krománok és alkalmazási eljárások
EP4212536C0 (en) BENZOXAZEPINE OXAZOLIDINONE COMPOUNDS AND METHODS OF USE
IL280863A (en) Autotaxin inhibitors and uses thereof
IL247262B (en) Cannabinoid compositions and uses
EP3344400A4 (en) Three dimensional microtissue bioprinter
PT3548033T (pt) Compostos e respectivos métodos de utilização
DK3331876T3 (da) Modulators of ror-gamma
PL3265448T3 (pl) Proleki riluzolu i ich zastosowanie
BR112018000129A2 (pt) oxiesteróis e seus métodos de utilização
IL251988A0 (en) Glycan-interacting compounds and methods of use
MA40933A (fr) Difluorométhyl-aminopyridines et difluorométhyl-aminopyrimidines
IL272200A (en) Isochroman compounds and uses thereof
DK3132009T3 (da) Fremgangsmåde
DK3283210T3 (da) Fremgangsmåde
PL3393468T3 (pl) Metody leczenia niedoboru odporności
BR112016025413A2 (pt) método de fabricação de um inserto e inserto
EP3398262A4 (en) MICRO-OUTER CHARACTERIZATION AND SELECTION
PT3337506T (pt) Combinações e suas utilizações
IL313083A (en) Terlipressin compositions and their methods of use
DK3368044T3 (da) Behandling af hepatisk steatose-relateret oligo-ovulation
IL254502B (en) Solid forms of menaquinols
EP3338088A4 (en) BIOMARKER FOR CORONARY DISEASE
IL248608A0 (en) Heparan sulphates